A randomized open-label trial on the use of budesonide/formoterol (Symbicort®) as an alternative reliever medication for mild to moderate asthmatic attacks

Table 2 Within-group analysis for objective analysis in both arms

Intervention	Variable	Mean (SD) or median (IQR)		p value
		Pre-	Post-
Symbicort ^®	¹Improvement in SaO₂	98.0 (3)%	99.0 (2)%	0.038
	¹Reduction in respiratory rate	18 (4)/min	16 (4)/min	0.001
	²Improvement in PEFR	196 (88.87) l/min	274.67 (119.75) l/min	< 0.001
Nebulized salbutamol	¹Improvement in SaO₂	97.0 (3)%	99.0 (2)%	0.039
	¹Reduction in respiratory rate	19 (4)/min	17 (2)/min	0.002
	²Improvement in PEFR	237.65 (100.59) l/min	327.06 (98.73) l/min	< 0.001

Note:
1. SaO₂ and respiratory rate are non-parametric data in both nebulized salbutamol and Symbicort^® arms. The values for both pre- and post-interventions are median and interquartile range values. Wilcoxon signed rank test was used for the analysis
2. PEFR is a parametric datum. The values for both pre- and post-interventions are mean and standard deviation values. Dependent t-test was used for the analysis

ISSN: 1865-1380